Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Latest Information Update: 29 Nov 2023
At a glance
- Drugs Etrasimod (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions
- Sponsors Arena Pharmaceuticals
- 17 Oct 2023 Results presented at the 31st United European Gastroenterology Week
- 27 Oct 2021 Results of post hoc analysis (n=216) assessing the effect of etrasimod on quality of life among participants who participated in Phase 2 trial (OASIS; NCT02447302) and open-label extension (OLE; NCT02536404) trials, presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2021.
- 28 Oct 2020 Results of pooled analysis from OASIS trial and its extension trial presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2020